Skye Bioscience, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 75.3K | $46.30K | 0.00% | Unchanged | 2026-03-31 |
| TwoSigma | quant | 25.7K | $15.79K | 0.00% | Trimmed-50.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.26 | — | — |
| 2026-05-11 | -0.32 | -0.32 | +1.03% |
| 2026-03-10 | -0.31 | -0.37 | -20.19% |
| 2025-11-10 | -0.32 | -0.32 | -1.22% |
| 2025-08-07 | -0.30 | -0.45 | -48.90% |
| 2025-05-08 | -0.29 | -0.28 | +3.45% |
| 2025-03-20 | -0.28 | -0.29 | -2.18% |
| 2024-11-07 | -0.25 | -0.10 | +59.08% |
| 2024-08-09 | -0.19 | -0.20 | -2.56% |
| 2024-05-10 | -0.16 | -0.18 | -12.50% |
| 2016-08-12 | -17.50 | -17.50 | — |
| 2016-05-13 | -17.50 | -20.00 | -14.29% |
| 2016-03-21 | -15.00 | -10.00 | +33.33% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| SKYE | -5.95% | +4.59% | +3.33% | -65.40% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -8.92% | +9.41% | +6.78% | -78.02% |